Moderated by Jonathan Pearson, Head of Healthcare UK, PA Consulting
The future for outpatient business models
Martin Henrichs, Managing Director, UBS
In 30 years time there may not be many inpatient hospitals. Here Martin looks at the viability of outpatient business models from acute to dentistry and from dialysis to rehab. Outpatient models offer huge advantages in cost, accessibility, convenience and safety. But how should today's medical professionals and operators transition to new outpatient models and what are the risks?
Reconfiguring acute care, driving into outpatient
Thomas Berglund, CEO, Capio
NASDAQ-quoted, pan-European group Capio runs hospitals, outpatient and ambulatory services across Scandinavia, Germany and France. Thomas, CEO since 2011, looks at how Capio has reconfigured acute delivery and at its focus on outpatient services, including the deployment of AI in primary care. What are the main barriers to change and how has Capio overcome them?
Building a primary care model in India - Kaushik Sen, CEO, Healthspring
Today in India, as in many Emerging Markets, sick patients often go straight to hospital. Primary care has a poor reputation and is often viewed as corrupt by patients. Here Kaushik gives a detailed overview of how primary care works in India and unpackages its potential, before describing Healthspring's business model, which has seen it grow to a network of 30 clinics.
The Fullerton Model and the outpatient sector in SE Asia and China
Ramesh Rajentheran, Group CFO & COO, Fullerton Health
Founded in 2011, Fullerton Health has grown rapidly, and now owns more than 225 medical centres across 6 countries with a network of more than 8,000 medical providers around the world. With a focus on the Asian outpatient sector, Fullerton Health aims to use technology and data analysis to transform healthcare across the region, making it more affordable and accessible. Who are Fullerton's customers and what do they want? Working with Microsoft, Fullerton has also pioneered AI/big data solutions to assess treatment choices and drug prescriptions against outcomes for particular patient populations, and also increasingly use their data to recommend more effective treatment options.